胃复春抗结直肠癌机制:网络药理学预测与实验验证
本研究采用网络药理学预测胃复春抗结直肠癌的活性成分与靶点,并在HCT116和SW620细胞及移植瘤小鼠模型中验证其对AKT和NF-κB信号通路的调控作用;回顾性队列初步探索显示术后联合化疗组在1、3、5年复发转移率有降低趋势。
要点
- 胃复春可能通过抑制AKT和NF-κB通路抑制结直肠癌细胞增殖、迁移并诱导凋亡。
- 体外实验显示胃复春降低p-AKT、p65、p-IκB并升高IκB蛋白水平。
- 回顾性队列提示术后胃复春联合化疗者1、3、5年复发转移率有降低趋势。
核心结论
- 胃复春可能通过调控AKT和NF-κB信号通路,调节结直肠癌细胞增殖、迁移和凋亡而发挥抗肿瘤作用。
研究设计与样本
- 研究含网络药理学分析、HCT116和SW620细胞体外实验及移植瘤小鼠模型验证。
- 另纳入接受根治性手术的结直肠癌患者进行回顾性队列分析,按术后是否接受胃复春治疗分为胃复春联合化疗组和单纯化疗组,并用倾向性评分匹配平衡基线特征。
主要发现
- 网络药理学识别67个生物活性化合物、211个治疗蛋白靶点、1699个疾病相关靶点、97个重叠靶点和187条相关信号通路。
- GO和KEGG分析显示胃复春调控细胞迁移、黏附、凋亡和细胞周期等过程,前20条肿瘤相关通路靶点主要富集于PI3K/Akt和NF-κB通路。
- 体外实验中胃复春显著抑制HCT116和SW620细胞增殖、迁移并诱导凋亡,降低AKT、p-AKT、p65、p-p65和p-IκB蛋白水平并升高IκB蛋白水平。
- 移植瘤小鼠模型中胃复春显著抑制结直肠癌肿瘤生长并下调AKT信号通路。
- 初步探索性分析观察到联合治疗组在1、3、5年复发和转移率有降低趋势。
临床怎么用
- 胃复春原有适应证为慢性胃炎、胃溃疡等胃部疾病,本研究提示其抗结直肠癌作用尚处探索阶段。
- 临床决策应结合患者具体情况,不宜仅依据本探索性结果将胃复春用于结直肠癌术后辅助治疗。
局限性
- 原文未报告回顾性队列的样本量、具体复发转移率数值及统计学显著性。
- 原文未报告细胞实验的具体浓度、时间及动物实验的剂量和样本量。
- 原文未报告倾向性评分匹配的具体变量和匹配后样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Weifuchun (WFC) is a kind of Chinese patent medicine, which is mainly used to treat chronic gastritis, gastric ulcer and other gastric diseases. However, the mechanism of Weifuchun in the treatment of Colorectal cancer (CRC) remains unclear. AIM OF THE STUDY: To investigate Weifuchun's anti-cancer efficacy against colorectal carcinoma and explore its underlying molecular mechanisms. MATERIALS AND METHODS: The TCMSP and BATMAN-TCM databases were employed to filter WFC's bioactive ingredients, while DrugBank provided information on their respective protein targets. The GeneCards and OMIM databases were queried to obtain CRC-associated targets, which were then cross-referenced with WFC targets via Venn diagram analysis to identify common targets. A network pharmacology approach was employed, using Cytoscape to visualize TCM compound-target-disease relationships, with subsequent functional and signaling pathway evaluation. Cell proliferations were detected by CCK-8, LDH, and colony forming assays. Flow cytometric analysis and Hoechst 33258 were used to detect apoptosis. Transwell assays were employed to detect the cell migration. AKT signaling pathway related protein expressions were detected by Western blot. Finally, immunohistochemistry and Western blot were analyzed to evaluate Ki-67 expression and AKT signaling pathway related proteins in the xenograft mouse model. This retrospective cohort study enrolled colorectal cancer patients who underwent curative-intent surgery. Based on whether they received treatment with WFC after surgery, the patients are divided into two groups: the WFC combined chemotherapy group (WFC group) and the chemotherapy-only group (control group). Propensity score matching (PSM) was employed to balance baseline characteristics between the two groups, enabling comparison of recurrence/metastasis rates. RESULTS: Our analysis identified 67 bioactive compounds, 211 therapeutic protein targets, 1699 disease-associated targets, with 97 overlapping targets and 187 relevant signaling pathways. Bioinformatics analysis through GO and KEGG databases revealed WFC's regulatory effects on cellular processes including cell migration, adhesion, apoptosis and cell cycle. Among the top 20 tumor-associated pathways identified, the targets predominantly localized to the PI3K/Akt and NF-κB signaling pathways. In vitro, WFC could significantly inhibit cell proliferation, migration, and induce apoptosis in HCT116 and SW620 cells. Molecular mechanism showed decreases in AKT, p-AKT, p65, p-65 and p-IκB proteins, and an increase in IκB protein level were observed in WFC treated-HCT116 and SW620 cells. Furthermore, WFC demonstrated significant inhibition of colorectal cancer (CRC) tumor growth in a xenograft mouse model, concomitant with downregulation of the AKT signaling pathway. Pilot exploratory analysis observed a trend toward lower recurrence and metastasis rates at 1, 3, and 5 years among patients receiving the combination therapy. CONCLUSION: WFC may exert its anti-tumor effect through modulation of the AKT and NF-κB signaling pathways, and then regulate proliferation, migration and apoptosis in colorectal cancer cells.
引用
- Zhang Z, Wang Z, Jiang Y, et al. Exploring the mechanisms of WeifuChun in colorectal cancer: Network pharmacology-based identification and experimental validation of key signaling pathways. J Ethnopharmacol. 2025. PMID: 40886867. doi:10.1016/j.jep.2025.120515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。